ClinicalTrials.gg
CompletedNCT03324113Updated Aug 5, 2025

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

A Phase 1 interventional study of SAR408701 and dexamethasone in Neoplasm Malignant, sponsored by Sanofi. Completed at 3 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Primary Objective:

  • To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors.

Secondary Objectives:

  • To characterize the overall safety profile of SAR408701 monotherapy.
  • To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites.
  • To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part.
  • To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity.
  • To assess the potential immunogenicity of SAR408701.
Read the detailed description

The study duration per participant will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an End-of-Treatment (EOT) visit around 30 days after the last administration of IMP, and at least one follow-up (FU) visit after the EOT visit.

02

Conditions studied

  • Neoplasm Malignant

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 34 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria:

  • Locally advanced or solid malignant tumor disease for which, in the judgement of the investigator, no standard alternative therapy is available.
  • Inclusion is likely to be expressing CEACAM5.
  • At least 6 x 5 μm slides from formalin-fixed paraffin-embedded (FFPE) should be available for retrospective central evaluation of CEACAM5 expression.
  • Patient understands and has signed the Written form and is willing and able to comply with the requirements of the trial.

Exclusion criteria:

  • Patient less than 20 years old.
  • (ECOG) performance status (PS) ≥2.
  • \<12 weeks.
  • Known or symptomatic (other than totally resected or previously irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.
  • Female patients of and male patients with female partners of childbearing potential who do not agree to use accepted and effective method of during the study treatment period and for 6 months following discontinuation of IMP.
  • Significant concomitant illnesses, including all severe medical conditions which, in the opinion of the Investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
  • Prior therapy targeting CEACAM5.
  • Prior maytansinoid treatments (maytansinoid derivative 1 [DM1] or maytansinoid derivative 4 [DM4] antibody drug conjugates).
  • Previous history and or unresolved corneal disorders.
  • Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYP) and for which a dose reduction cannot be considered.
  • Medical conditions requiring concomitant administration of strong inhibitor, unless it can be discontinued at least 2 weeks before first administration of SAR408701.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    SAR408701 Monotherapy

    SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors

    Drug: SAR408701 · Drug: dexamethasone · Drug: naphazoline · Drug: diphenhydramine

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Tusamitamab ravtansine

  • Pharmaceutical form: solution for eye drop Route of administration: eye drop

    Also known as: Santeson ophthalmic solution

  • Drugnaphazoline

    Pharmaceutical form: solution for eye drop Route of administration: eye drop

    Also known as: Clearine

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Restamin Kowa

06

What researchers measure

Primary outcomes

  1. IMP-related dose limiting toxicities (DLT)

    IMP-related DLTs are defined as adverse events (AE) related to the IMPs in absence of clear evidence to the contrary, after validation by the Study Committee, and if not related to a disease progression, graded using National Cancer Institute common Toxicity Criteria (NCI-CTC) scale v4.03

    Time frame: 4 weeks, Dose escalation q3w part: 3 weeks

Secondary outcomes

  1. Treatment emergent adverse events

    Overall safety profile characterized in terms of the type, frequency, severity, seriousness, and relationship to study therapy of any AEs based on standard and systematic assessment including physical findings, laboratory tests or other investigations

    Time frame: Up to an average of 9 months

  2. Maximum observed concentration (Cmax) of SAR408701

    Cmax for SAR408701 will be assessed after single and repeat doses, as relevant

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  3. Cmax of DM4 and Me-DM4

    Cmax for DM4 and Me-DM4 will be assessed after single and repeat doses, as relevant

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  4. Time to reach maximum concentration (Tmax) of SAR408701

    Tmax for SAR408701 will be assessed after single and repeat doses, as relevant

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  5. Tmax of DM4 and Me-DM4

    Tmax for DM4 and Me-DM4 will be assessed after single and repeat doses, as relevant

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  6. Area under the concentration-time curve (AUC) of SAR408701

    AUC of SAR408701 from time zero extrapolated to infinity

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  7. AUC of DM4 and Me-DM4

    AUC of DM4 and Me-DM4 from time zero extrapolated to infinity

    Time frame: Main dose-escalation part: Cycle 1 and Cycle 4 (each cycle is 14 days); Dose-escalation bis part with loading dose: Cycle 1 (Cycle 1 is 14 days), Dose-escalation q3w part: Cycle 1 and Cycle2 day 1 (Cycle 1 is 21 days)

  8. Assessment of PDy effect

    Assessment of plasma CEACAM5 levels in main dose-escalation part

    Time frame: Up to an average of 10 months

  9. Assessment of anti-tumor activity

    Assessment of tumor response using standard imaging, as defined by RECIST 1.1 criteria

    Time frame: Up to an average of 10 months

  10. Detection of anti-SAR408701 antibody

    Immunogenicity evaluation for anti-SAR408701 antibodies

    Time frame: Up to an average of 10 months

07

Study locations

3 sites
  • Investigational Site Number : 3920002
    Nagoya, Aichi-ken 464-8681, Japan
  • Investigational Site Number : 3920003
    Kashiwa-shi, Chiba 277-8577, Japan
  • Investigational Site Number : 3920001
    Sunto-gun, Shizuoka 411-8777, Japan
08

References and documents

Publications

  • Muro K, Yamazaki K, Kadowaki S, Mishima S, Kawakami T, Tanaka T, Tada K, Fagniez N, Ohshima S, Yoshino T. Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors. Int J Clin Oncol. 2025 Aug;30(8):1522-1536. doi: 10.1007/s10147-025-02784-4. Epub 2025 May 25. PubMed 40413667 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2022, 61 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 61 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 27, 2017
StartActual
Oct 17, 2017
Primary completionActual
Nov 18, 2022
CompletionActual
Dec 26, 2022
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03324113
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Oct 17, 2017
Primary completion
Nov 18, 2022
Completion
Dec 26, 2022
Last update
Aug 5, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tusamitamab ravtansine

Start the discussion